NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial

Key Takeaways Novocure's Phase 3 PANOVA-3 trial met its primary endpoint with a two-month median survival benefit. NVCR's TTFields therapy showed higher one-year survival rates than chemotherapy alone in the trial. Novocure's TTFields improved pain-free survival and quality of life, with favorable safety outcomes.Novocure (NVCR) recently announced positive top-line results from its pivotal Phase 3 PANOVA-3 trial, evaluating Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-p ...